Avelumab (anti-PD-L1) is under evaluation in a Phase II trial (NCT03006848), while apatinib plus camrelizumab improved PFS in PD-L1-positive advanced osteosarcoma (79). This evidence concerns the gene CD274 and osteosarcoma.